Global Uveitis Market Report 2018: Insights, Epidemiology and Market Forecasts to 2027 – Vimpat was the Best Selling Drug in 2016 Followed by Lamictal and Keppra – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Uveitis - Market Insights, Epidemiology and Market Forecasts to 2027" drug pipelines has been added to ResearchAndMarkets.com's offering. Uveitis market is expected to grow during the forecasted period of 2018-2027 owing to the launch of nine drugs (presently in Phase III). Uveitis Therapeutics market has seen a global sales of 5.4 billion in 2016. The three best selling drugs were Vimpat (UCB), Lamictal (Glaxosmithkline) and Keppra (UCB) with Vimpat recording high